|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:acquired
|
gptkb:Ovation_Pharmaceuticals
gptkb:H._Lundbeck_A/_S
|
|
gptkbp:acquisition
|
Lundbeck acquired Ovation Pharmaceuticals in 2009
Lundbeck acquired the rights to Brintellix in 2013
Lundbeck acquired the rights to Sabril in 2009
|
|
gptkbp:awards
|
received multiple industry awards
|
|
gptkbp:ceo
|
gptkb:Deborah_Dunsire
|
|
gptkbp:clinical_trial
|
multiple ongoing trials
focuses on CNS disorders
conducts clinical trials for new drugs
|
|
gptkbp:collaboration
|
collaborates with academic institutions
|
|
gptkbp:community_engagement
|
engages with local communities
|
|
gptkbp:conducts_research_on
|
Lundbeck Research
|
|
gptkbp:employees
|
approximately 5,000
|
|
gptkbp:founded
|
1915
|
|
gptkbp:founder
|
gptkb:Hans_Lundbeck
|
|
gptkbp:global_presence
|
operates in over 50 countries
|
|
gptkbp:headquarters
|
gptkb:Copenhagen,_Denmark
|
|
gptkbp:history
|
has a long history in the pharmaceutical industry
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lundbeck
|
|
gptkbp:industry
|
gptkb:pharmaceuticals
|
|
gptkbp:innovation
|
invests in innovative drug development
|
|
gptkbp:invention
|
holds numerous patents in pharmaceuticals
|
|
gptkbp:investment
|
invests in research and development
|
|
gptkbp:leadership
|
led by a diverse management team
|
|
gptkbp:market
|
operates in the global market
|
|
gptkbp:market_cap
|
approximately 10 billion EUR
|
|
gptkbp:mission
|
dedicated to improving the quality of life for patients.
|
|
gptkbp:partnership
|
gptkb:Takeda_Pharmaceutical_Company
gptkb:H._Lundbeck_A/_S
gptkb:Otsuka_Pharmaceutical
|
|
gptkbp:partnerships
|
forms partnerships with other companies
|
|
gptkbp:philanthropy
|
supports mental health initiatives
|
|
gptkbp:products
|
gptkb:Brintellix
gptkb:Cipralex
gptkb:Sabril
gptkb:Abilify
|
|
gptkbp:regulatory_compliance
|
receives regulatory approvals for its products
|
|
gptkbp:research_areas
|
focuses on mental health and CNS disorders
|
|
gptkbp:research_focus
|
gptkb:depression
gptkb:neurodegenerative_diseases
schizophrenia
|
|
gptkbp:revenue
|
approximately 2.5 billion EUR
|
|
gptkbp:specializes_in
|
psychiatry
|
|
gptkbp:stock_exchange
|
gptkb:NASDAQ_Copenhagen
|
|
gptkbp:subsidiary
|
gptkb:Lundbeck_A/_S
gptkb:Lundbeck_LLC
gptkb:Lundbeck_Research_USA
gptkb:Lundbeck_Ltd.
|
|
gptkbp:sustainability
|
committed to sustainable practices
|
|
gptkbp:training
|
provides training for employees
|
|
gptkbp:website
|
www.lundbeck.com
|
|
gptkbp:bfsParent
|
gptkb:Neurocrine_Biosciences
|
|
gptkbp:bfsLayer
|
5
|